CORC

在结果中检索

CORC

浏览/检索结果: 共13条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial 期刊论文
ONCOTARGETS AND THERAPY, 2018, 卷号: 11
作者:  Wu, Yi-Long;  Xu, Chong-Rui;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun
收藏  |  浏览/下载：16/0  |  提交时间：2019/12/04
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 卷号: 11, 期号: 1
作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/04
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial 期刊论文
ONCOTARGETS AND THERAPY, 2018, 卷号: 11
作者:  Lu, Shun;  Wu, Yi-Long;  Huang, Yunchao;  Hu, Cheng-Ping;  Li, Wei
收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung 期刊论文
ONCOTARGETS AND THERAPY, 2018, 卷号: 11
作者:  Zhang, Li;  Cseh, Agnieszka;  Peil, Barbara;  Wang, Jie;  Feng, Jifeng
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer 期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2
作者:  Ouyang, Xuenong;  Shi, Meiqi;  Jie, Fangwei;  Bai, Yuxian;  Shen, Peng
收藏  |  浏览/下载：28/0  |  提交时间：2019/12/05
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study 会议论文
作者:  Wu, Yi-Long;  Lu, Shun;  Cheng, Ying;  Zhou, Caicun;  Wang, Jie
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文
The Patient - Patient-Centered Outcomes Research, 2018, 卷号: 11, 期号: 1, 页码: 131-141
作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03
Plasma Hemopexin ameliorates murine spinal cord injury by switching microglia from the M1 state to the M2 state. 期刊论文
Cell Death Dis, 2018, 卷号: Vol.9 No.2, 页码: 181
作者:  Feng,Jifeng;  Yuan,Yimin;  Liu,Weili;  Yu,Zhongwang;  Yin,Dou
收藏  |  浏览/下载：6/0  |  提交时间：2019/04/24
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. 期刊论文
OncoTargets and therapy, 2018, 卷号: Vol.11, 页码: 8575-8587
作者:  Wu Yi-Long;  Xu Chong-Rui;  Hu Cheng-Ping;  Feng Jifeng;  Lu Shun
收藏  |  浏览/下载：11/0  |  提交时间：2019/02/25
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer 期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2
作者:  Ouyang, Xuenong;  Shi, Meiqi;  Jie, Fangwei;  Bai, Yuxian;  Shen, Peng
收藏  |  浏览/下载：26/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace